#Paris #France #GLP-1 #Havas Health #Shape Shifting

Havas Health Network Unveils GLP-1 Consultancy in France

On March 13, 2025, Havas Health Network is set to launch its groundbreaking GLP-1 consultancy in Paris through a flagship event titled "Shape Shifting: A Close Look at the Health and Wellness Disruptor - GLP-1". This initiative will gather thought leaders, brand experts, and healthcare professionals to discuss the revolutionary effects of GLP-1 treatments emerging in the European market.

Bridging Health, Creativity, and Technology

Havas aims to highlight its commitment to innovation at this event, emphasizing its role at the intersection of health, creativity, and technology. This consultancy initiative is designed to provide unique insights to clients, industry partners, and brand marketers navigating the rapidly growing GLP-1 sector.

Inspired by the success of the GLP101 Day, which was hosted in New York last November, the event in Paris seeks to unite European experts to explore the science behind GLP-1 medications and their transformative influence on healthcare and consumer markets. This fresh initiative aims to equip European brand and marketing leaders with actionable insights as they adapt to this global revolution and understand its market implications.

The Impact of GLP-1 on Consumer Health

GLP-1 therapeutics are not only changing weight loss options but also altering consumer behaviors across various health and wellness domains. In the U.S., these medications have already revolutionized the healthcare landscape and are significantly influencing both the consumer goods and lifestyle sectors. Estimates predict that the global GLP-1 market could reach $5.56 billion by 2030, driven by new drug launches and the rising prevalence of diabetes in high-income countries.

Chloé Depiesse, Managing Director of Havas Health Network, acknowledges the similarities and unique cultural nuances between the North American and European markets that could affect treatment adoption and consumer engagement beyond the healthcare sphere. "Additional insights from Europe will allow us to fine-tune our approach to meet local needs and stay ahead of developments in this fast-evolving area," she stated.

A Commitment to Innovative Solutions

Anna Maria Marra, Havas's Executive Director for Europe, expressed the network's goal to deliver innovative solutions tailored to the new demands of the European market. She emphasized the importance of educating clients and partners about GLP-1 treatments and their growing application throughout Europe.

As Havas Health Network embarks on this new consultancy venture, it looks set to illuminate the transformative potential of GLP-1 for health and wellness in Europe. The insights gained from events like "Shape Shifting" will be invaluable as brands adapt their strategies in this rapidly evolving landscape.

For further information about Havas Health Network's GLP-1 consultancy and how your brand can navigate this new environment, you can visit their website.

Learn More

To access Havas's GLP-1 Prosumer Report and gain deeper insights, click here.

References: Mordor Intelligence, Report on Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market